This review summarises key product characteristics for CUVITRU® and how it has performed during pivotal clinical trials when used to treat patients with primary immunodeficiency diseases, in terms of efficacy, tolerability and patient acceptability.
It also provides commentary and recommendations from Matthew Cook, Professor of Medicine at Australian National University (ANU), Director of Immunology at Canberra Hospital and Co-Director of the Centre for Personalised Immunology. He is a clinician-scientist with clinical and research interests in primary immune deficiency and immune dysregulation disorders.
Please login below to download this issue (PDF)